Anti-Nogo-A antibody treatment six months post-stroke results in neuroplasticity and improved functional outcome

 Where is the protocol located and what is the delivery mechanism to all 10 million yearly stroke survivors? NOT medical staff: they have completely proven not to read and implement research! WHOM will be doing human testing?

Anti-Nogo-A antibody treatment six months post-stroke results in neuroplasticity and improved functional outcome

Author links open overlay panel

, , , , ,

https://doi.org/10.1016/j.expneurol.2025.115306

Get rights and content

Under a Creative Commons license

Open access

Abstract

We have reported that anti-Nogo-A antibody therapy is effective in enhancing neuroplasticity and improving functional recovery when given up to two months post-stroke. Here we assessed whether this therapy would be effective at a much later time point post-stroke. Rats underwent middle cerebral artery occlusion to permanently impair their preferred forelimb and six months later were given either anti-Nogo-A antibody, control antibody or no antibody. Rats receiving anti-Nogo-A antibody showed significant behavioral improvement that correlated with cortico-rubral plasticity, indicating that anti-Nogo-A antibody is effective even long after the injury has occurred, opening the treatment window for many stroke survivors.